94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Heinz Wiendl1*†
Frederik Barkhof2,3
Xavier Montalban4
Anat Achiron5,6
Tobias Derfuss7
Andrew Chan8
Suzanne Hodgkinson9
Alexandre Prat10Letizia Leocani11,12,13
Klaus Schmierer14,15
Finn Sellebjerg16,17
Patrick Vermersch18Hulin Jin19Anita Chudecka20Andreas Kloetgen19Dongdong Lin21Lidia Gardner22
Nicola De Stefano23- 1Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany
- 2Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands
- 3Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, United Kingdom
- 4Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain
- 5Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel
- 6Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
- 7Department of Neurology, University Hospital Basel, Basel, Switzerland
- 8Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- 9Ingham Institute for Applied Medical Research, University of New South Wales Medicine and Liverpool Hospital, Sydney, NSW, Australia
- 10Department of Neurosciences, Université de Montréal, Montréal, QC, Canada
- 11Department of Neurology, University Vita-Salute San Raffaele, Milan, Italy
- 12Experimental Neurophysiology Unit, Scientific Institute IRCCS San Raffaele, Milan, Italy
- 13Department of Neurorehabilitation Science, Casa di Cura Igea, Milan, Italy
- 14The Blizard Institute, Centre for Neuroscience, Surgery and Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
- 15Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS, Trust, London, United Kingdom
- 16Danish MS Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark
- 17Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 18Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France
- 19Clinical Measurement Sciences, Merck Healthcare KGaA, Darmstadt, Germany
- 20Clinical Research Services, Cytel Inc., Geneva, Switzerland
- 21Clinical Measurement Sciences, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, United States
- 22Neurology & Immunology Medical Unit, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, United States
- 23Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
A Corrigendum on
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
By Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L and De Stefano N (2025) Front. Immunol. 16:1512189. doi: 10.3389/fimmu.2025.1512189
In the published article, there was an error in Figure 5 as published. In the figure, the legend for the blue and red dots incorrectly read as “|FC| <1.2 & FDR>0.05”. The legend for blue should read “|FC| <1.2 & FDR<0.05” and for red should read “|FC| >1.2 & FDR<0.05”. The corrected Figure 5 and its caption “Gene expression of CD3+ and CD19+ cells at M12, M15 and M24 compared to BL. BL, baseline; FC, fold change; FDR, false discovery rate; M, month.” appear below.
Figure 5
Figure 5. Gene expression of CD3+ and CD19+ cells at M12, M15 and M24 compared to BL. BL, baseline; FC, fold change; FDR, false discovery rate; M, month.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: multiple sclerosis, cladribine tablets, biomarkers, transcriptomics, immunophenotyping, immune reconstitution therapy
Citation: Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L and De Stefano N (2025) Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Front. Immunol. 16:1571978. doi: 10.3389/fimmu.2025.1571978
Received: 06 February 2025; Accepted: 24 February 2025;
Published: 05 March 2025.
Edited and Reviewed by:
Klaus Berek, Innsbruck Medical University, AustriaCopyright © 2025 Wiendl, Barkhof, Montalban, Achiron, Derfuss, Chan, Hodgkinson, Prat, Leocani, Schmierer, Sellebjerg, Vermersch, Jin, Chudecka, Kloetgen, Lin, Gardner and De Stefano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Heinz Wiendl, aGVpbnoud2llbmRsQHVuaWtsaW5pay1mcmVpYnVyZy5kZQ==
†Present address: Heinz Wiendl, Department of Neurology and Neurophysiology, Freiburg University, Freiburg, Germany